Tatsuro Hayashi1, Takeshi Yuasa2, Sho Uehara3, Yasushi Inoue3, Shinya Yamamoto3, Hitoshi Masuda3, Yasuhisa Fujii3, Iwao Fukui3, Junji Yonese3. 1. Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Ariake, 135-8550, Japan. s9078@nms.ac.jp. 2. Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Ariake, 135-8550, Japan. takeshi.yuasa@jfcr.or.jp. 3. Department of Urology, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Ariake, 135-8550, Japan.
Abstract
BACKGROUND: The outcome of treatment of Japanese patients with urachal cancer is not well known. The purpose of this study is to clarify the characteristics and outcomes of Japanese patients with urachal cancer. MATERIALS AND METHODS: The medical records of patients with urachal cancer who were treated in our hospital between 1994 and 2014 were retrospectively reviewed and statistically analyzed. RESULTS: We found 28 patients who had been diagnosed with urachal cancer and treated in our hospital during the study period. The median age of these patients was 52.3 years [interquartile range (IQR), 46.0-56.8 years]. Seventeen patients underwent surgery in our department. The median observation period of these patients was 42.6 months (IQR, 21.1-49.7 months). Among patients who had undergone surgery, cancer recurred in 7 (41 %). The estimated median time from surgery to recurrence and overall survival (OS) period were 35.8 months [95 % confidence interval (CI), 7.7 months-not determined] and not reached, respectively. Seventeen patients received chemotherapy for metastatic disease. The estimated median OS time from initial metastasis was 23.5 months (95 % CI, 11.8-33.3 months). CONCLUSIONS: Urachal cancer is usually locally advanced at presentation and it has a high risk of distant metastases. However, long-term survival following surgical treatment occurs in a significant fraction of patients. This study indicates the current treatment results for patients with urachal cancer in Japanese clinical practice. To establish a standard operation method and chemotherapy, a multicenter, prospective study is needed in a larger population in the future.
BACKGROUND: The outcome of treatment of Japanese patients with urachal cancer is not well known. The purpose of this study is to clarify the characteristics and outcomes of Japanese patients with urachal cancer. MATERIALS AND METHODS: The medical records of patients with urachal cancer who were treated in our hospital between 1994 and 2014 were retrospectively reviewed and statistically analyzed. RESULTS: We found 28 patients who had been diagnosed with urachal cancer and treated in our hospital during the study period. The median age of these patients was 52.3 years [interquartile range (IQR), 46.0-56.8 years]. Seventeen patients underwent surgery in our department. The median observation period of these patients was 42.6 months (IQR, 21.1-49.7 months). Among patients who had undergone surgery, cancer recurred in 7 (41 %). The estimated median time from surgery to recurrence and overall survival (OS) period were 35.8 months [95 % confidence interval (CI), 7.7 months-not determined] and not reached, respectively. Seventeen patients received chemotherapy for metastatic disease. The estimated median OS time from initial metastasis was 23.5 months (95 % CI, 11.8-33.3 months). CONCLUSIONS:Urachal cancer is usually locally advanced at presentation and it has a high risk of distant metastases. However, long-term survival following surgical treatment occurs in a significant fraction of patients. This study indicates the current treatment results for patients with urachal cancer in Japanese clinical practice. To establish a standard operation method and chemotherapy, a multicenter, prospective study is needed in a larger population in the future.
Entities:
Keywords:
Chemotherapy; Clinical outcome; Partial cystectomy; Sheldon classification; Urachal cancer
Authors: Christine Elser; Joan Sweet; Sendhil K Cheran; Masoom A Haider; Michael Jewett; Srikala S Sridhar Journal: Can Urol Assoc J Date: 2012-02 Impact factor: 1.862
Authors: Richard A Ashley; Brant A Inman; Thomas J Sebo; Bradley C Leibovich; Michael L Blute; Eugene D Kwon; Horst Zincke Journal: Cancer Date: 2006-08-15 Impact factor: 6.860
Authors: Jehonathan H Pinthus; Riad Haddad; John Trachtenberg; Eric Holowaty; Jeff Bowler; Andrew M Herzenberg; Michael Jewett; Neil E Fleshner Journal: J Urol Date: 2006-06 Impact factor: 7.450
Authors: Anuradha Gopalan; David S Sharp; Samson W Fine; Satish K Tickoo; Harry W Herr; Victor E Reuter; Semra Olgac Journal: Am J Surg Pathol Date: 2009-05 Impact factor: 6.394
Authors: Julian R Molina; J Fernando Quevedo; Alfred F Furth; Ronald L Richardson; Horst Zincke; Patrick A Burch Journal: Cancer Date: 2007-12-01 Impact factor: 6.860
Authors: Henning Reis; Ulrich Krafft; Christian Niedworok; Orsolya Módos; Thomas Herold; Mark Behrendt; Hikmat Al-Ahmadie; Boris Hadaschik; Peter Nyirady; Tibor Szarvas Journal: Dis Markers Date: 2018-03-12 Impact factor: 3.434
Authors: Young Dong Yu; Young Hwii Ko; Jong Wook Kim; Seung Il Jung; Seok Ho Kang; Jinsung Park; Ho Kyung Seo; Hyung Joon Kim; Byong Chang Jeong; Tae-Hwan Kim; Se Young Choi; Jong Kil Nam; Ja Yoon Ku; Kwan Joong Joo; Won Sik Jang; Young Eun Yoon; Seok Joong Yun; Sung-Hoo Hong; Jong Jin Oh Journal: Front Oncol Date: 2021-05-31 Impact factor: 6.244